CN Patent

CN107257858B — 乳酸脱氢酶的治疗性抑制及其试剂

Assigned to Novo Nordisk Health Care AG · Expires 2022-03-08 · 4y expired

What this patent protects

本发明涉及通过使用dsRNAs例如Dicer底物siRNA(DsiRNA)试剂而用于降低乳酸脱氢酶靶标RNA和蛋白质水平的化合物、组合物和方法。

USPTO Abstract

本发明涉及通过使用dsRNAs例如Dicer底物siRNA(DsiRNA)试剂而用于降低乳酸脱氢酶靶标RNA和蛋白质水平的化合物、组合物和方法。

Drugs covered by this patent

nedosiran-sodium (NEDOSIRAN SODIUM)

Patent Metadata

Patent number: CN107257858B
Jurisdiction: CN
Classification: —
Expires: 2022-03-08
Drug substance claim: No
Drug product claim: No
Assignee: Novo Nordisk Health Care AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.